The estimated Net Worth of Sean A Power is at least $25.1 Million dollars as of 3 January 2024. Mr. Power owns over 47,867 units of TG Therapeutics Inc stock worth over $14,002,775 and over the last 12 years he sold TGTX stock worth over $10,237,590. In addition, he makes $815,560 as Chief Financial Officer, Treasurer und Corporate Secretary at TG Therapeutics Inc.
Sean has made over 17 trades of the TG Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 47,867 units of TGTX stock worth $809,431 on 3 January 2024.
The largest trade he's ever made was selling 84,965 units of TG Therapeutics Inc stock on 4 January 2022 worth over $1,622,832. On average, Sean trades about 26,720 units every 127 days since 2012. As of 3 January 2024 he still owns at least 606,969 units of TG Therapeutics Inc stock.
You can see the complete history of Mr. Power stock trades at the bottom of the page.
Sean A. Power CPA serves as Chief Financial Officer, Treasurer, Corporate Secretary of the Company. Mr. Power joined the Company from Keryx Biopharmaceuticals, Inc., where he served as Corporate Controller from 2006 to 2011. During his tenure there, Mr. Power was involved in all capital raising and licensing transactions. He was also responsible for leading Keryx’s compliance with SEC rules and regulations. Prior to joining Keryx, he was with KPMG, LLP, independent certified public accountants. Additionally, Mr. Power served as Chief Financial Officer of Opus Point Partners, LLC from 2011 to 2019. Mr. Power received a B.B.A in accounting from Siena College and is a member of the American Institute of Certified Public Accountants.
As the Chief Financial Officer, Treasurer und Corporate Secretary of TG Therapeutics Inc, the total compensation of Sean Power at TG Therapeutics Inc is $815,560. There are 2 executives at TG Therapeutics Inc getting paid more, with Michael Weiss having the highest compensation of $12,674,700.
Sean Power is 38, he's been the Chief Financial Officer, Treasurer und Corporate Secretary of TG Therapeutics Inc since 2011. There are 9 older and no younger executives at TG Therapeutics Inc. The oldest executive at TG Therapeutics Inc is William Kennedy, 75, who is the Independent Director.
Sean's mailing address filed with the SEC is 3020 CARRINGTON MILL BLVD, SUITE 475, MORRISVILLE, NC, 27560.
Over the last 12 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss und Sean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
TG Therapeutics Inc executives and other stock owners filed with the SEC include: